Summary

Global postpartum hemorrhage treatment devices market is expected to reach USD 1,452.63 million by 2032 from USD 997.66 million in 2024, growing at a CAGR of 4.9% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Postpartum Hemorrhage Treatment Devices Market, By Type (Uterine Balloon Tamponade, Uniject Prefilled Injection System, Non-Pneumatic Anti-Shock Garment, Vacuum-Induced Hemorrhage Control Devices, and Others), Condition (Major Postpartum Hemorrhage (More Than 1000 ML), Minor Postpartum Hemorrhage (500-1000 ML), and Massive Postpartum Hemorrhage (2000 ML or More), Secondary Postpartum Hemorrhage), Patient Type (Primary PPH and Secondary PPH), End User (Hospitals, Maternity Centers, Specialty Clinics, Home Care Settings, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Netherlands, Switzerland, Norway, Austria, Ireland, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Chile, Peru, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends & Forecast To 2032



Overview of Global Postpartum Hemorrhage Treatment Dynamics:

Driver
• Rising incidence of postpartum hemorrhage

Restraint

• Side effects associated with the postpartum hemorrhage treatment

Opportunity

• Training and educational programs for proper use of PPH treatment devices

• Market Players:

The key market players operating in the global postpartum hemorrhage treatment devices market are listed below:

• Coagulant Therapeutics
• Sterimed Group
• RevMedx
• Maternova Inc.
• Sinapi Biomedical
• BD
• Organon group of companies
• Laborie
• CooperCompanies
• Belmont Medical Technologies
• Utah Medical Products, Inc
• ANGIPLAST PRIVATE LIMITED
• Krishco Medical Products Pvt. Ltd.
• 3rd Stone Design
• Advin Health Care

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 61
1.1 OBJECTIVES OF THE STUDY 61
1.2 MARKET DEFINITION 61
1.3 OVERVIEW OF THE GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET 62
1.4 LIMITATIONS 63
1.5 MARKETS COVERED 63
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 MULTIVARIATE MODELLING 72
2.7 TYPE LIFELINE CURVE 73
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
2.9 DBMR MARKET POSITION GRID 75
2.10 VENDOR SHARE ANALYSIS 76
2.11 MARKET END USER COVERAGE GRID 77
2.12 SECONDARY SOURCES 78
2.13 ASSUMPTIONS 78
3 EXECUTIVE SUMMARY 79
4 PREMIUM INSIGHTS 83
4.1 PESTAL ANALYSIS 87
4.2 PORTERS FIVE FORCES ANALYSIS 88
4.3 INDUSTRY INSIGHTS 89
4.3.1 MICRO AND MACROECONOMIC FACTORS 89
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING 89
4.3.3 KEY PRICING STRATEGIES 89
4.4 COST ANALYSIS BREAKDOWN 90
4.5 TECHNOLOGY ROADMAP 90
4.6 VALUE CHAIN ANALYSIS 91
4.7 OPPORTUNITY MAP ANALYSIS 91
4.8 HEALTHCARE ECONOMY 91
4.9 REIMBURSEMENT FRAMEWORK 92
 
4.10 TARIFFS AND ITS IMPACT ON THE MARKET 93
4.10.1 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 93
4.10.2 GLOBAL VS. REGIONAL TARIFF STRUCTURES 93
4.10.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 93
4.10.4 TARIFF REGULATIONS IN KEY MARKETS 94
4.10.4.1 MEDICARE/MEDICAID TARIFF POLICIES 94
4.10.4.2 CMS PRICING MODELS 94
4.10.4.3 OTHERS 94
4.10.5 TARIFFS ON MEDICAL DEVICES & EQUIPMENT 94
4.10.5.1 IMPORT/EXPORT DUTIES ON MEDICAL EQUIPMENT 94
4.10.5.2 IMPACT ON PRICING AND AVAILABILITY OF HIGH-END MEDICAL TECHNOLOGY 94
4.10.5.3 CASE STUDIES OF TARIFF CHANGES AFFECTING THE INDUSTRY 95
4.10.6 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 95
4.10.7 TARIFF EXEMPTIONS AND INCENTIVES 95
4.10.8 DUTY-FREE IMPORTS FOR ESSENTIAL MEDICINES AND VACCINES 95
4.10.9 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 96
4.10.10 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 96
5 REGULATORY FRAMEWORK 97
6 MARKET OVERVIEW 100
6.1 DRIVERS 102
6.1.1 RISING INCIDENCE OF POSTPARTUM HAEMORRHAGE 102
6.1.2 ONGOING TECHNOLOGICAL ADVANCEMENTS FOR POSTPARTUM HEMORRHAGE TREATMENTS 103
6.1.3 RISING BIRTH RATES ASSOCIATED WITH AN INCREASE IN THE NUMBER OF POSTPARTUM HEMORRHAGE 104
6.1.4 REGULATORY SUPPORT AND APPROVALS ASSOCIATED WITH THE TREATMENT DEVICES 105
6.2 RESTRAINTS 106
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE POSTPARTUM HEMORRHAGE TREATMENT 106
6.2.2 LIMITED RESEARCH AND DEVELOPMENT FOR PPH TREATMENT 107
6.3 OPPORTUNITIES 108
6.3.1 TRAINING AND EDUCATIONAL PROGRAMS FOR PROPER USE OF PPH TREATMENT DEVICES 108
6.3.2 SUPPORT FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS IN PPH DEVICE ADOPTION 109
6.3.3 TELEMEDICINE INTEGRATION TO ENHANCE POSTPARTUM HEMORRHAGE DEVICE USE 110
6.4 CHALLENGES 111
6.4.1 ENVIRONMENTAL IMPACT AND DISPOSAL ISSUES OF SINGLE-USE PPH DEVICES 111
6.4.2 STERILITY CHALLENGES AND INFECTION RISKS IN PPH DEVICES 112
 
7 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY TYPE 113
7.1 OVERVIEW 114
7.2 UTERINE BALLOON TAMPONADE 117
7.2.1 BAKRI BALLOON 118
7.2.1.1 BAKRI POSTPARTUM BALLOON 118
7.2.1.2 BAKRI POSTPARTUM BALLOON WITH RAPID INSTILLATION COMPONENTS 118
7.2.2 FOLEY CATHETER 119
7.2.2.1 STANDARD FOLEY CATHETER 119
7.2.2.2 CONDOM-LOADED FOLEY CATHETER 119
7.3 UNIJECT PREFILLED INJECTION SYSTEM 120
7.3.1 OXYTOCIN-BASED INJECTION SYSTEM 120
7.3.2 CARBETOCIN-BASED INJECTION SYSTEM 120
7.4 NON-PNEUMATIC ANTI-SHOCK GARMENT 121
7.4.1 STANDARD NON-PNEUMATIC ANTI-SHOCK GARMENT 122
7.4.1.1 MEDIUM 122
7.4.1.2 LARGE 122
7.4.2 MODIFIED NON-PNEUMATIC ANTI-SHOCK GARMENT 122
7.4.2.1 MEDIUM 122
7.4.2.2 LARGE 122
7.5 VACUUM-INDUCED HEMORRHAGE CONTROL DEVICES 123
7.5.1 JADA SYSTEM 123
7.5.2 OTHERS 123
7.6 OTHERS 124
7.6.1 COMPRESSION DEVICES 125
7.6.1.1 B-LYNCH 125
7.6.1.2 HAYMAN 125
7.6.1.3 OTHER 125
7.6.2 UTERINE ARTERY LIGATION PRODUCTS 125
7.6.3 OTHERS 125
8 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY PATIENT TYPE 126
8.1 OVERVIEW 127
8.2 PRIMARY PPH 130
8.3 SECONDARY PPH 131
 
9 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY CONDITION 132
9.1 OVERVIEW 133
9.2 MAJOR POSTPARTUM HEMORRHAGE (MORE THAN 1000 ML) 136
9.3 MINOR POSTPARTUM HEMORRHAGE (500-1000 ML) 137
9.4 MASSIVE POSTPARTUM HEMORRHAGE (2000 ML OR MORE) 138
9.5 SECONDARY POSTPARTUM HEMORRHAGE 138
10 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY DISTRIBUTION CHANNEL 139
10.1 OVERVIEW 140
10.2 DIRECT TENDER 143
10.3 RETAIL SALES 144
10.3.1 OFFLINE SALES 144
10.3.2 ONLINE SALES 144
10.4 OTHERS 145
11 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY END USER 146
11.1 OVERVIEW 147
11.2 HOSPITALS 150
11.2.1 PUBLIC HOSPITALS 151
11.2.1.1 TIER 2 151
11.2.1.2 TIER 3 151
11.2.1.3 TIER 1 151
11.2.2 PRIVATE HOSPITALS 152
11.2.2.1 TIER 2 152
11.2.2.2 TIER 3 152
11.2.2.3 TIER 1 152
11.3 MATERNITY CENTERS 153
11.4 SPECIALTY CLINICS 154
11.5 HOME CARE SETTINGS 154
11.6 OTHERS 155
 
12 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY REGION 156
12.1 OVERVIEW 157
12.2 NORTH AMERICA 160
12.2.1 U.S. 167
12.2.2 CANADA 174
12.2.3 MEXICO 180
12.3 EUROPE 186
12.3.1 GERMANY 193
12.3.2 FRANCE 199
12.3.3 U.K. 205
12.3.4 ITALY 211
12.3.5 SPAIN 217
12.3.6 RUSSIA 223
12.3.7 TURKEY 229
12.3.8 NETHERLAND 235
12.3.9 POLAND 241
12.3.10 BELGIUM 247
12.3.11 SWITZERLAND 253
12.3.12 SWEDEN 259
12.3.13 DENMARK 265
12.3.14 NORWAY 271
12.3.15 FINLAND 277
12.3.16 REST OF EUROPE 283
12.4 ASIA-PACIFIC 284
12.4.1 CHINA 291
12.4.2 JAPAN 297
12.4.3 INDIA 304
12.4.4 AUSTRALIA 311
12.4.5 SOUTH KOREA 318
12.4.6 INDONESIA 325
12.4.7 THAILAND 331
12.4.8 MALAYSIA 337
12.4.9 SINGAPORE 343
12.4.10 PHILIPPINES 349
12.4.11 VIETNAM 355
12.4.12 TAIWAN 361
12.4.13 NEW ZEALAND 367
12.4.14 REST OF ASIA-PACIFIC 373
12.5 SOUTH AMERICA 374
12.5.1 BRAZIL 381
12.5.2 ARGENTINA 388
12.5.3 REST OF SOUTH AMERICA 394
12.6 MIDDLE EAST AND AFRICA 395
12.6.1 SOUTH AFRICA 402
12.6.2 SAUDI ARABIA 408
12.6.3 EGYPT 414
12.6.4 U.A.E. 420
12.6.5 KUWAIT 426
12.6.6 QATAR 432
12.6.7 OMAN 438
12.6.8 BAHRAIN 444
12.6.9 REST OF MIDDLE EAST AND AFRICA 450
13 GLOBAL POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET: COMPANY LANDSCAPE 451
13.1 COMPANY SHARE ANALYSIS: GLOBAL 451
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 452
13.3 COMPANY SHARE ANALYSIS: EUROPE 453
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 454
14 SWOT ANALYSIS 455
15 COMPANY PROFILES 456
15.1 BD 456
15.1.1 COMPANY SNAPSHOT 456
15.1.2 REVENUE ANALYSIS 457
15.1.3 COMPANY SHARE ANALYSIS 457
15.1.4 SOLUTION PORTFOLIO 458
15.1.5 RECENT NEWS 458
15.2 ORGANON GROUP OF COMPANIES 459
15.2.1 COMPANY SNAPSHOT 459
15.2.2 REVENUE ANALYSIS 459
15.2.3 COMPANY SHARE ANALYSIS 460
15.2.4 PRODUCT PORTFOLIO 460
15.2.5 RECENT DEVELOPMENTS/NEWS 461
 
15.3 LABORIE 462
15.3.1 COMPANY SNAPSHOT 462
15.3.2 COMPANY SHARE ANALYSIS 462
15.3.3 PRODUCT PORTFOLIO 463
15.3.4 RECENT DEVELOPMENT 463
15.4 COOPERCOMPANIES 464
15.4.1 COMPANY SNAPSHOT 464
15.4.2 REVENUE ANALYSIS 464
15.4.3 COMPANY SHARE ANALYSIS 465
15.4.4 PRODUCT PORTFOLIO 465
15.4.5 RECENT DEVELOPMENT 465
15.5 BELMONT MEDICAL TECHNOLOGIES 466
15.5.1 COMPANY SNAPSHOT 466
15.5.2 COMPANY SHARE ANALYSIS 466
15.5.3 PRODUCT PORTFOLIO 467
15.5.4 RECENT DEVELOPMENT 467
15.6 ADVIN HEALTH CARE 468
15.6.1 COMPANY SNAPSHOT 468
15.6.2 PRODUCT PORTFOLIO 468
15.6.3 RECENT DEVELOPMENTS 468
15.7 ANGIPLAST PRIVATE LIMITED 469
15.7.1 COMPANY SNAPSHOT 469
15.7.2 PRODUCT PORTFOLIO 469
15.7.3 RECENT DEVELOPMENT 469
15.8 COAGULANT THERAPEUTICS 470
15.8.1 COMPANY SNAPSHOT 470
15.8.2 PIPELINE PORTFOLIO 470
15.8.3 RECENT DEVELOPMENT 470
15.9 KRISHCO MEDICAL PRODUCTS PVT. LTD 471
15.9.1 COMPANY SNAPSHOT 471
15.9.2 PRODUCT PORTFOLIO 471
15.9.3 RECENT DEVELOPMENT 472
15.10 MATERNOVA INC. 473
15.10.1 COMPANY SNAPSHOT 473
15.10.2 PRODUCT PORTFOLIO 473
15.10.3 RECENT DEVELOPMENT 473
 
15.11 REVMEDX 474
15.11.1 COMPANY SNAPSHOT 474
15.11.2 PRODUCT PORTFOLIO 474
15.11.3 RECENT DEVELOPMENT 474
15.12 3RD STONE DESIGN 475
15.12.1 COMPANY SNAPSHOT 475
15.12.2 PRODUCT PORTFOLIO 475
15.12.3 RECENT DEVELOPMENTS 475
15.13 STERIMED GROUP 476
15.13.1 COMPANY SNAPSHOT 476
15.13.2 PRODUCT PORTFOLIO 476
15.13.3 RECENT DEVELOPMENTS 476
15.14 UTAH MEDICAL PRODUCTS, INC. 477
15.14.1 COMPANY SNAPSHOT 477
15.14.2 REVENUE ANALYSIS 477
15.14.3 PRODUCT PORTFOLIO 478
15.14.4 RECENT DEVELOPMENTS 478
15.15 SINAPI BIOMEDICAL 479
15.15.1 COMPANY SNAPSHOT 479
15.15.2 PRODUCT PORTFOLIO 479
15.15.3 RECENT DEVELOPMENTS 479
16 QUESTIONNAIRE 480